Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Cryan J et al. | FKBP, the binding protein for the immunosuppressive drug, FK-506, is not an inhibitor of protein kinase C activity. | 1991 | Biochem. Biophys. Res. Commun. | pmid:1719972 |
Ryu S and Yasunami Y | Prevention of immune rejection in rat islet allografts by continuous SC administration of FK 506 using a mini-osmotic pump. | 1991 | Transplant. Proc. | pmid:1703710 |
Karlsson H et al. | The immunosuppressive agent FK506 inhibits in vitro expression of membrane-bound and soluble interleukin-2 receptors on resting but not on activated human lymphocytes. | 1991 | Immunol. Lett. | pmid:1720417 |
Alejandro R et al. | Combined liver-islet allotransplantation in man under FK 506. | 1991 | Transplant. Proc. | pmid:1703712 |
Wu YM et al. | Interaction between FK 506 and cyclosporine in dogs. | 1991 | Transplant. Proc. | pmid:1721281 |
Woo J et al. | Kinetics of early T-cell repopulation in the mouse following syngeneic bone marrow transplantation: FK 506 causes a maturational defect of CD4+ CD8- T cells. | 1991 | Transplant. Proc. | pmid:1721313 |
Mieles LA et al. | Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. | 1991 | Transplant. Proc. | pmid:1721344 |
Nakazato P et al. | Early experience with FK 506 induction immunosuppression--suggestion for using oral FK 506. | 1991 | Transplant. Proc. | pmid:1721345 |
Ueda D et al. | Influence of FK 506 on renal blood flow. | 1991 | Transplant. Proc. | pmid:1721377 |
Thomson AW et al. | The influence of FK 506 on the thymus: implications of drug-induced injury to thymic epithelial cells. | 1991 | Transplant. Proc. | pmid:1703361 |
Shinozuka H et al. | Effect of FK 506 on experimental liver carcinogenesis. | 1991 | Transplant. Proc. | pmid:1721407 |
Pelekanou V et al. | FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function. | 1991 | Transplant. Proc. | pmid:1721408 |
Sato K et al. | Comparative study of FK 506, cyclosporine, and triple regimen immunosuppression with FK 506, cyclosporine, and mizoribine. | 1991 | Transplant. Proc. | pmid:1721440 |
Ringe D | Immunosuppression. Binding by design. | 1991 | Nature | pmid:1710317 |
Tropschug M and Hofmann R | FK506 and protein kinase C. | 1991 | Nature | pmid:1710319 |
Nelson PA et al. | cDNA encoding murine FK506-binding protein (FKBP): nucleotide and deduced amino acid sequence. | 1991 | Gene | pmid:1722474 |
Haba T et al. | Pathological and immunohistochemical examination in the rat treated with FK 506. | 1991 | Transplant. Proc. | pmid:1714649 |
Gailliot FP et al. | Fluidized bed adsorption for whole broth extraction. | 1990 Sep-Oct | Biotechnol. Prog. | pmid:1366874 |
Naouri A and Tissot E | [Indications for liver transplantation in adults]. | 1990 Jun-Jul | J Chir (Paris) | pmid:1698800 |
MacLeod AM and Thomson AW | [FK-506. A new immunosuppressive drug]. | 1990 Jul-Sep | Medicina (Firenze) | pmid:1706817 |
Wasik M et al. | Effect of FK-506 and cyclosporine on human T and B lymphoproliferative responses. | 1990 Jul-Aug | Immunopharmacology | pmid:1699911 |
Morris RE et al. | Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. | 1990 | Transplant. Proc. | pmid:1689885 |
Li PK et al. | The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506. | 1990 | Adverse Drug React Acute Poisoning Rev | pmid:1703724 |
Todo S et al. | Early trials with FK 506 as primary treatment in liver transplantation. | 1990 | Transplant. Proc. | pmid:1689886 |
McCauley J et al. | The effects of FK 506 on renal function after liver transplantation. | 1990 | Transplant. Proc. | pmid:1689887 |
Kang Y et al. | Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation. | 1990 | Transplant. Proc. | pmid:1689889 |
Jain AB et al. | FK 506 dosage in human organ transplantation. | 1990 | Transplant. Proc. | pmid:1689890 |
Demetris AJ et al. | Pathologic observations in human allograft recipients treated with FK 506. | 1990 | Transplant. Proc. | pmid:1689891 |
Shapiro R et al. | The side effects of FK 506 in humans. | 1990 | Transplant. Proc. | pmid:1689892 |
Woo J et al. | The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis. | 1990 | Scand. J. Immunol. | pmid:1690915 |
Yasunami Y et al. | FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. | 1990 | Transplantation | pmid:1691535 |
Metcalfe SM and Richards FM | Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. | 1990 | Transplantation | pmid:1691537 |
Morimoto T et al. | Pancreaticoduodenal allotransplantation with FK 506 in the dog. | 1990 | Transplant. Proc. | pmid:1691550 |
Yasunami Y et al. | Characterization of the immunosuppressive activity of FK 506 in rat islet allografts. | 1990 | Transplant. Proc. | pmid:1691557 |
Thomson AW | FK-506 enters the clinic. | 1990 | Immunol. Today | pmid:1692221 |
Saitoh Y et al. | Morphological rejection phases and cytotoxic activity in peripheral blood lymphocytes in canine lung allo-transplantation. | 1990 | Jpn J Surg | pmid:1692892 |
Murase N et al. | Prevention of spontaneous diabetes in BB rats with FK 506. | 1990 | Lancet | pmid:1697397 |
Justice RM et al. | The detection of proline isomerase activity in FK506-binding protein by two-dimensional 1H NMR exchange spectroscopy. | 1990 | Biochem. Biophys. Res. Commun. | pmid:1697463 |
Todo S et al. | Liver, kidney, and thoracic organ transplantation under FK 506. | 1990 | Ann. Surg. | pmid:1697743 |
Sakr MF et al. | FK 506 ameliorates the hepatic injury associated with ischemia. | 1990 | Life Sci. | pmid:1698241 |
Kurasawa K et al. | The immunosuppressant FK-506 prevents progression of diabetes in nonobese diabetic mice. | 1990 | Clin. Immunol. Immunopathol. | pmid:1698584 |
Miyagawa J et al. | Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetic mice. | 1990 | Diabetologia | pmid:1698679 |
Lagodzinski Z et al. | Effect of FK506 and cyclosporine on primary and secondary skin allograft survival in mice. | 1990 | Immunology | pmid:1698713 |
Mattila PS et al. | The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. | 1990 | EMBO J. | pmid:1702384 |
Kawashima H et al. | Antigen-specific suppressor cells induced by FK506 in experimental autoimmune uveoretinitis in the rat. | 1990 | Invest. Ophthalmol. Vis. Sci. | pmid:1702408 |
Wilkinson PC and Watson EA | FK506 and pertussis toxin distinguish growth-induced locomotor activation from attractant-stimulated locomotion in human blood lymphocytes. | 1990 | Immunology | pmid:1702750 |
Metcalfe S and Milner J | Phosphatases PP1 and PP2A act after the G0/G1 interface in lymphocyte activation. | 1990 | Immunol. Lett. | pmid:1702753 |
Takada K et al. | Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection. | 1990 | J. Chromatogr. | pmid:1703552 |
Woo J et al. | Antigen presentation and HLA-DR expression by FK-506-treated human monocytes. | 1990 | Immunology | pmid:1703987 |
Fung JJ et al. | Overview of FK506 in transplantation. | 1990 | Clin Transpl | pmid:1715740 |